CMC Regulatory Paradigm Shift To Be Reviewed By PQRI
FDA will look to the Product Quality Research Institute to help with the manufacturing science issues involved in reshaping the agency's NDA chemistry, manufacturing and controls regulatory paradigm
You may also be interested in...
FDA's restructuring of the Office of New Drug Chemistry includes the establishment of four new divisions to separate out pre- and post-marketing functions
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials